The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) hit a new 52-week low and has $7.60 target or 13.00% below today’s $8.74 share price. The 8 months bearish chart indicates high risk for the $186.94 million company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $7.60 price target is reached, the company will be worth $24.30M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 23,856 shares traded hands. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has declined 32.11% since March 14, 2016 and is downtrending. It has underperformed by 37.72% the S&P500.
Analysts await Concert Pharmaceuticals Inc (NASDAQ:CNCE) to report earnings on November, 3. They expect $-0.63 earnings per share, down 61.54% or $0.24 from last year’s $-0.39 per share. After $-0.60 actual earnings per share reported by Concert Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% negative EPS growth.
Concert Pharmaceuticals Inc (NASDAQ:CNCE) Ratings Coverage
Out of 7 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. $32.0 is the highest target while $21 is the lowest. The $27.80 average target is 218.08% above today’s ($8.74) stock price. Concert Pharmaceuticals has been the topic of 9 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The rating was initiated by Aegis Capital with “Buy” on Wednesday, September 9. TH Capital maintained Concert Pharmaceuticals Inc (NASDAQ:CNCE) rating on Tuesday, September 22. TH Capital has “Buy” rating and $32.0 price target. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. Brean Capital initiated Concert Pharmaceuticals Inc (NASDAQ:CNCE) rating on Wednesday, August 12. Brean Capital has “Buy” rating and $21 price target. The stock has “Buy” rating given by Roth Capital on Tuesday, September 22. The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) has “Neutral” rating given on Monday, November 9 by UBS. Stifel Nicolaus initiated Concert Pharmaceuticals Inc (NASDAQ:CNCE) on Friday, July 1 with “Buy” rating.
According to Zacks Investment Research, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.”
Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.36, from 1.03 in 2016Q1. The ratio improved, as 8 funds sold all Concert Pharmaceuticals Inc shares owned while 25 reduced positions. 11 funds bought stakes while 35 increased positions. They now own 13.09 million shares or 2.13% less from 13.37 million shares in 2016Q1.
The Massachusetts-based Acadian Asset Management Ltd Co has invested 0.02% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). Blackrock Investment Mgmt Lc last reported 0% of its portfolio in the stock. Teachers Advsr Incorporated reported 24,624 shares or 0% of all its holdings. California State Teachers Retirement Sys has 34,570 shares for 0% of their US portfolio. Principal Grp Inc holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 112,700 shares. Numeric Invsts Lc accumulated 0.06% or 618,598 shares. Blackrock, a New York-based fund reported 2,411 shares. Rockefeller holds 8,600 shares or 0% of its portfolio. Fmr Lc holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 55,175 shares. Globeflex Cap Ltd Partnership reported 16,761 shares or 0.05% of all its holdings. Cornerstone Capital Mgmt Hldgs Ltd Limited Liability Company holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 5,000 shares. Goldman Sachs Grp Inc last reported 0% of its portfolio in the stock. Blackrock last reported 3,447 shares in the company. Point72 Asset Mgmt Limited Partnership last reported 404,479 shares in the company. Moreover, Ladenburg Thalmann Services Inc has 0% invested in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 142 shares.
More important recent Concert Pharmaceuticals Inc (NASDAQ:CNCE) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on February 14, 2014, also Businesswire.com published article titled: “Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and …”, Businesswire.com published: “Concert Pharmaceuticals Expands Management Team” on September 06, 2016. More interesting news about Concert Pharmaceuticals Inc (NASDAQ:CNCE) was released by: Businesswire.com and their article: “Concert Pharmaceuticals Announces $8 Million Milestone from Celgene” with publication date: October 08, 2015.
CNCE Company Profile
Concert Pharmaceuticals, Inc., incorporated on April 12, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of small molecule drugs. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. The Firm has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Firm is utilizing its DCE Platform to discover and develop product candidates for a range of indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.